What SS-31 / Elamipretide is
Elamipretide is a mitochondria-targeted peptide studied for effects on cardiolipin-associated mitochondrial function.
SS-31 / Elamipretide is grouped under Longevity + Skin / Approved / Clinical on PeptideFactCheck because it is a serious clinical-stage mitochondrial peptide that overlaps with longevity audience interest without relying only on forum claims.
The useful starting point is to separate the molecule itself from the internet story around it. It is one of the more serious clinical-stage mitochondrial peptide stories.
Why people keep looking it up
People connect SS-31 with mitochondrial performance, fatigue, aging, and cellular energy.
Elamipretide is designed to target mitochondria and interact with cardiolipin-associated mitochondrial function.
SS-31 / Elamipretide tends to stay in the conversation because it touches a familiar public theme: mitochondria, cardiolipin, and cellular energetics. That makes it easy for the claim to travel faster than the evidence.
What the evidence can support right now
Human trials exist in disease contexts. That does not prove healthy-person optimization claims.
Human clinical trials exist in disease contexts, but outcomes and regulatory status must be evaluated by indication.
Preclinical research supports mitochondrial targeting and cellular energetics hypotheses.
Why this page carries the current tier: Human trials and mechanistic rationale, but no broad approval status in this V1 profile.
The current seed trail for SS-31 / Elamipretide is pulling from 1 literature source, 1 trials source, and 1 databases source.
Safety, limits, and regulatory context
Disease-specific trial results should not be generalized to healthy optimization.
Elamipretide is treated here as clinical or investigational unless a current official label is added to the source trail.
Editorial boundary: PeptideFactCheck does not publish dosing, cycling, sourcing, injection, or administration instructions for SS-31 / Elamipretide. The job here is to explain the public claim, the mechanism story, the evidence strength, and the current limits.
Molecular and identifier data
The current PubChem match for SS-31 / Elamipretide is CID 11764719. That gives the page a source-backed chemistry record rather than a placeholder identifier block.
- PubChem CID
- 11764719
- Formula
- C32H49N9O5
- Molecular weight
- 639.8
- InChIKey
- SFVLTCAESLKEHH-WKAQUBQDSA-N
Matched synonyms include Elamipretide, 736992-21-5, bendavia, MTP-131, Ocuvia, SS-31, MTP 131, Szeto-schiller peptide.
Open PubChem recordClinical trial snapshot
The current ClinicalTrials.gov intervention query for SS-31 / Elamipretide returns 1 study records. This does not prove efficacy by itself, but it does show whether the peptide is showing up in a formal trial registry rather than only in forums or vendor copy.
Literature snapshot
The current PubMed query for SS-31 / Elamipretide returns 433 results. The articles below are a quick literature surface so the page shows actual papers instead of only generic evidence labels.
Label and regulatory records
For approved or clinically developed peptides, the page now pulls in official labeling and FDA-facing records where they exist. That makes the regulatory section materially more useful than a generic approved or not-approved tag.
- Brand names
- FORZINITY
- Generic names
- ELAMIPRETIDE HYDROCHLORIDE
- Routes
- SUBCUTANEOUS
- Application numbers
- NDA215244
Indications and usage. 1 INDICATIONS AND USAGE FORZINITY is indicated to improve muscle strength in adult and pediatric patients with Barth syndrome weighing at least 30 kg. This indication is approved under accelerated approval based on an improvement in knee extensor muscle strength, an intermediate clinical endpoint [see Clinical Studies (14) ] . Continued approval for this indication may be contingent upon verification and description...
Warnings and cautions. 5 WARNINGS AND PRECAUTIONS Benzyl alcohol toxicity : Do not use in neonates. ( 5.1 ) 5.1 Risk of Benzyl Alcohol Toxicity in Neonates FORZINITY is not approved for use in neonates. Serious adverse reactions, including fatal reactions, of new onset or worsening metabolic acidosis that progressed to neurotoxicity, and in some cases gasping syndrome, have been reported in low-birth weight neonates (less than 2,500 grams...
Contraindications. 4 CONTRAINDICATIONS Serious hypersensitivity to elamipretide or any of the excipients in FORZINITY [see Warnings and Precautions (5.2) ]. Serious hypersensitivity to any of the ingredients ( 4 , 5.2 )
Source trail
Each linked source is shown directly so the page can be audited. The page now combines its editorial seed trail with automated official-source enrichment generated on 2026-04-24 from PubChem, ClinicalTrials.gov, PubMed, DailyMed, openFDA label, and Drugs@FDA.